A Phase 1, Open-Label Study to Evaluate the Effect of Rifampin or Itraconazole on the Pharmacokinetics of GDC-0032 in Healthy Subjects
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2016
Price : $35 *
At a glance
- Drugs Taselisib (Primary) ; Itraconazole; Rifampicin
- Indications Bacterial infections; Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Genentech
- 02 Mar 2016 Study design changed from non-randomized to randomized as reported by ClinicalTrials.gov record.
- 01 Aug 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 23 Mar 2013 New trial record